Cognitive neuroscience treatment research to improve cognition in schizophrenia II: Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders

Cameron S Carter, Deanna M. Barch, Edward Bullmore, James Breiling, Robert W. Buchanan, Pamela Butler, Jonathan D. Cohen, Mark Geyer, Randy Gollub, Michael F. Green, Judith Jaeger, John H. Krystal, Holly Moore, Keith Nuechterlein, Trevor Robbins, Steven Silverstein, Edward E. Smith, Milton Strauss, Til Wykes

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative, funded by an R13 from the National Institute of Mental Health, seeks to enhance translational research in treatment development for impaired cognition in schizophrenia by developing tools from cognitive neuroscience into useful measures of treatment effects on behavior and brain function. An initial series of meetings focused on the selection of a new set of tasks from cognitive neuroscience for the measurement of treatment effects on specific cognitive and neural systems. Subsequent validation and optimization studies are underway and a subset of validated measures with well-characterized psychometric properties will be generally available in 2011. This article describes results of the first meeting of the second phase of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia, which seeks to develop imaging biomarkers and improved animal models to enhance translational research. In this meeting, we considered issues related to the use of methods such as functional magnetic resonance imaging, electroencephalography, magnetoencephalography, and transcranial magnetic simulation as biomarkers for treatment development. We explored the biological nature of the signals measured by each method, their validity and reliability as measures of cognition-related neural activity, potential confounds related to drug effects on the signal of interest, and conceptual, methodological, and pragmatic issues related to their use in preclinical, first into human, and multicenter phase II and III studies. This overview article describes the background and goals of the meeting together with a summary of the major issues discussed in more detail in the accompanying articles appearing in this issue of Biological Psychiatry.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalBiological Psychiatry
Volume70
Issue number1
DOIs
StatePublished - Jul 1 2011

Fingerprint

Cognition
Schizophrenia
Biomarkers
Translational Medical Research
Research
Biological Psychiatry
National Institute of Mental Health (U.S.)
Magnetoencephalography
Validation Studies
Psychometrics
Reproducibility of Results
Electroencephalography
Animal Models
Magnetic Resonance Imaging
Cognitive Neuroscience
Brain
Pharmaceutical Preparations

Keywords

  • Biomarker
  • CNTRICS
  • cognition
  • schizophrenia
  • treatment

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Cognitive neuroscience treatment research to improve cognition in schizophrenia II : Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. / Carter, Cameron S; Barch, Deanna M.; Bullmore, Edward; Breiling, James; Buchanan, Robert W.; Butler, Pamela; Cohen, Jonathan D.; Geyer, Mark; Gollub, Randy; Green, Michael F.; Jaeger, Judith; Krystal, John H.; Moore, Holly; Nuechterlein, Keith; Robbins, Trevor; Silverstein, Steven; Smith, Edward E.; Strauss, Milton; Wykes, Til.

In: Biological Psychiatry, Vol. 70, No. 1, 01.07.2011, p. 7-12.

Research output: Contribution to journalArticle

Carter, CS, Barch, DM, Bullmore, E, Breiling, J, Buchanan, RW, Butler, P, Cohen, JD, Geyer, M, Gollub, R, Green, MF, Jaeger, J, Krystal, JH, Moore, H, Nuechterlein, K, Robbins, T, Silverstein, S, Smith, EE, Strauss, M & Wykes, T 2011, 'Cognitive neuroscience treatment research to improve cognition in schizophrenia II: Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders', Biological Psychiatry, vol. 70, no. 1, pp. 7-12. https://doi.org/10.1016/j.biopsych.2011.01.041
Carter, Cameron S ; Barch, Deanna M. ; Bullmore, Edward ; Breiling, James ; Buchanan, Robert W. ; Butler, Pamela ; Cohen, Jonathan D. ; Geyer, Mark ; Gollub, Randy ; Green, Michael F. ; Jaeger, Judith ; Krystal, John H. ; Moore, Holly ; Nuechterlein, Keith ; Robbins, Trevor ; Silverstein, Steven ; Smith, Edward E. ; Strauss, Milton ; Wykes, Til. / Cognitive neuroscience treatment research to improve cognition in schizophrenia II : Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. In: Biological Psychiatry. 2011 ; Vol. 70, No. 1. pp. 7-12.
@article{fa585237f01345ab86ad1bafb8711708,
title = "Cognitive neuroscience treatment research to improve cognition in schizophrenia II: Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders",
abstract = "The Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative, funded by an R13 from the National Institute of Mental Health, seeks to enhance translational research in treatment development for impaired cognition in schizophrenia by developing tools from cognitive neuroscience into useful measures of treatment effects on behavior and brain function. An initial series of meetings focused on the selection of a new set of tasks from cognitive neuroscience for the measurement of treatment effects on specific cognitive and neural systems. Subsequent validation and optimization studies are underway and a subset of validated measures with well-characterized psychometric properties will be generally available in 2011. This article describes results of the first meeting of the second phase of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia, which seeks to develop imaging biomarkers and improved animal models to enhance translational research. In this meeting, we considered issues related to the use of methods such as functional magnetic resonance imaging, electroencephalography, magnetoencephalography, and transcranial magnetic simulation as biomarkers for treatment development. We explored the biological nature of the signals measured by each method, their validity and reliability as measures of cognition-related neural activity, potential confounds related to drug effects on the signal of interest, and conceptual, methodological, and pragmatic issues related to their use in preclinical, first into human, and multicenter phase II and III studies. This overview article describes the background and goals of the meeting together with a summary of the major issues discussed in more detail in the accompanying articles appearing in this issue of Biological Psychiatry.",
keywords = "Biomarker, CNTRICS, cognition, schizophrenia, treatment",
author = "Carter, {Cameron S} and Barch, {Deanna M.} and Edward Bullmore and James Breiling and Buchanan, {Robert W.} and Pamela Butler and Cohen, {Jonathan D.} and Mark Geyer and Randy Gollub and Green, {Michael F.} and Judith Jaeger and Krystal, {John H.} and Holly Moore and Keith Nuechterlein and Trevor Robbins and Steven Silverstein and Smith, {Edward E.} and Milton Strauss and Til Wykes",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.biopsych.2011.01.041",
language = "English (US)",
volume = "70",
pages = "7--12",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Cognitive neuroscience treatment research to improve cognition in schizophrenia II

T2 - Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders

AU - Carter, Cameron S

AU - Barch, Deanna M.

AU - Bullmore, Edward

AU - Breiling, James

AU - Buchanan, Robert W.

AU - Butler, Pamela

AU - Cohen, Jonathan D.

AU - Geyer, Mark

AU - Gollub, Randy

AU - Green, Michael F.

AU - Jaeger, Judith

AU - Krystal, John H.

AU - Moore, Holly

AU - Nuechterlein, Keith

AU - Robbins, Trevor

AU - Silverstein, Steven

AU - Smith, Edward E.

AU - Strauss, Milton

AU - Wykes, Til

PY - 2011/7/1

Y1 - 2011/7/1

N2 - The Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative, funded by an R13 from the National Institute of Mental Health, seeks to enhance translational research in treatment development for impaired cognition in schizophrenia by developing tools from cognitive neuroscience into useful measures of treatment effects on behavior and brain function. An initial series of meetings focused on the selection of a new set of tasks from cognitive neuroscience for the measurement of treatment effects on specific cognitive and neural systems. Subsequent validation and optimization studies are underway and a subset of validated measures with well-characterized psychometric properties will be generally available in 2011. This article describes results of the first meeting of the second phase of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia, which seeks to develop imaging biomarkers and improved animal models to enhance translational research. In this meeting, we considered issues related to the use of methods such as functional magnetic resonance imaging, electroencephalography, magnetoencephalography, and transcranial magnetic simulation as biomarkers for treatment development. We explored the biological nature of the signals measured by each method, their validity and reliability as measures of cognition-related neural activity, potential confounds related to drug effects on the signal of interest, and conceptual, methodological, and pragmatic issues related to their use in preclinical, first into human, and multicenter phase II and III studies. This overview article describes the background and goals of the meeting together with a summary of the major issues discussed in more detail in the accompanying articles appearing in this issue of Biological Psychiatry.

AB - The Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative, funded by an R13 from the National Institute of Mental Health, seeks to enhance translational research in treatment development for impaired cognition in schizophrenia by developing tools from cognitive neuroscience into useful measures of treatment effects on behavior and brain function. An initial series of meetings focused on the selection of a new set of tasks from cognitive neuroscience for the measurement of treatment effects on specific cognitive and neural systems. Subsequent validation and optimization studies are underway and a subset of validated measures with well-characterized psychometric properties will be generally available in 2011. This article describes results of the first meeting of the second phase of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia, which seeks to develop imaging biomarkers and improved animal models to enhance translational research. In this meeting, we considered issues related to the use of methods such as functional magnetic resonance imaging, electroencephalography, magnetoencephalography, and transcranial magnetic simulation as biomarkers for treatment development. We explored the biological nature of the signals measured by each method, their validity and reliability as measures of cognition-related neural activity, potential confounds related to drug effects on the signal of interest, and conceptual, methodological, and pragmatic issues related to their use in preclinical, first into human, and multicenter phase II and III studies. This overview article describes the background and goals of the meeting together with a summary of the major issues discussed in more detail in the accompanying articles appearing in this issue of Biological Psychiatry.

KW - Biomarker

KW - CNTRICS

KW - cognition

KW - schizophrenia

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=79958803157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958803157&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2011.01.041

DO - 10.1016/j.biopsych.2011.01.041

M3 - Article

C2 - 21529781

AN - SCOPUS:79958803157

VL - 70

SP - 7

EP - 12

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 1

ER -